Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
433 hedge funds and large institutions have $15.5B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2020 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 153 increasing their positions, 141 reducing their positions, and 38 closing their positions.
211% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 38
48% more capital invested
Capital invested by funds: $10.5B → $15.5B (+$5.04B)
43% more funds holding in top 10
Funds holding in top 10: 23 → 33 (+10)
22% more funds holding
Funds holding: 354 → 433 (+79)
9% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 141
24% less call options, than puts
Call options by funds: $102M | Put options by funds: $134M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$626M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$114M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103M |
| 4 |
HM
HealthCor Management
New York
|
+$95.6M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$165M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$122M |
| 3 |
Renaissance Technologies
New York
|
-$105M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$80.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$78.6M |
HZNP Hedge Fund Activity: Q3 2020 in Review
433 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2020, worth a combined $15.5B — up 48% from $10.5B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new HZNP positions and 38 closed out — a net gain of 80 holders — while 153 added to existing stakes and 141 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $626M. The largest seller was Citadel Advisors, cutting an estimated $165M.
- 433 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2020, up from 354 in Q2 2020.
- Funds reported $15.5B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2020, up 48% quarter-over-quarter.
- 118 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2020 and 38 closed out, a net change of +80 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2020 was Fidelity Investments, an estimated $626M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2020 was Citadel Advisors, an estimated $165M sold.
Based on aggregated 13F filings for Q3 2020.